FDA Extends Sparsentan (Filspari) sNDA Review for Focal Segmental Glomerulosclerosis
Sparsentan (Filspari), a dual endothelin-angiotensin receptor antagonist, produced greater and earlier proteinuria reduction than irbesartan in focal segmental glomerulosclerosis, though the phase 3 DUPLEX trial did not show a significant difference in eGFR slope.
Category
Regulatory
Source
FDA
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.